Royalties on the Arrowhead deal are not disclosed. Looking at the layout of payments I would guess 15% - 20%. With BP almost certainly insisting on rights for all leronlimab indications or at least first option on other indications, more cash up front and low royalties would be a bad decision for Cytodyn.